The Primary Care Companion for CNS Disorders

CME Institute

Home | About Us | Mission Statement | All CME Activities | MyCME | CME Facebook | CME Twitter

JCP

Home | About JCP | Subscribe | Archive | Information for Authors | Information for Reviewers | Information for Advertisers | CNS Job Market | Customer Service | JCP Facebook | JCP Twitter

PCC

Home | About PCC | Register | Archive | Information for Authors | Information for Reviewers | PCC Facebook | PCC Twitter

Help

FAQ | About Psychiatrist.com | Terms of use | Privacy policy

magnifying glass for search

  • magnifying glass for search
  • Advanced Search

Login

Login  
Login | Login Help | Register | Subscribe
Register | Elerts

Quick Links

Font: A | A | A

Top

Purchase PDF

Vol 19, No 5
Table of Contents

Facebook ShareShare

twitter shareTweet This

envelope iconEmail a link

Related ►

Related Articles

[X]

<p class="frontmatter-fieldnotes disclaimernew" style="margin-bottom:15px;">This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s <a href="/pages/termsofuse.aspx" target="_blank">Terms & Conditions</a>.</p> <div id="_idContainer000">
  <p class="ltrs-br-ltr-br-title"><span class="bold"><a id="_idTextAnchor000"></a>Bright Light Therapy for Negative Symptoms</span></p>
  <p class="ltrs-br-ltr-br-body-text"><span class="semibold">To the Editor:</span> Since Kraepelin’s description,<span class="htm-cite"><a href="#ref1">1</a></span> negative symptoms have been considered central to schizophrenia. Negative symptoms cause serious personal, social, and occupational functioning disability in schizophrenia patients. As pharmacologic strategies are frequently insufficient in the treatment of negative symptoms, alternative treatment approaches are required. Aichhorn et al<span class="htm-cite"><a href="#ref2">2</a></span> showed that bright light therapy improved negative symptoms in residual schizophrenia. In contrast, a recent study<span class="htm-cite"><a href="#ref3">3</a></span> revealed that bright light therapy did not improve negative symptoms but exacerbated general psychopathology. To date, the effect of bright light therapy on negative symptoms has been rarely studied, and no definite conclusion regarding its efficacy has been determined. We describe a case of residual schizophrenia in which negative symptoms were improved by bright light therapy.</p>
  <p class="ltrs-br-ltr-br-body-text">&nbsp;</p>
  <p class="ltrs-br-ltr-br-body-text"><span class="semibold-ital">Case report.</span> A 66-year-old male inpatient with schizophrenia demonstrated severe negative symptoms. He had suffered from schizophrenia since the age of 19 years and had several hospitalizations at local psychiatric hospitals. His auditory hallucinations were exacerbated after his mother’s death, and he was referred to our hospital at the age of 56 years. After admission, his auditory hallucinations improved, but his negative symptoms persisted. He spent most of his time sitting in his room in an inert state. His persistent negative symptoms did not improve with administration of aripiprazole 6 mg/d. He was diagnosed with residual schizophrenia (<span class="italic">ICD-10</span> code F295.6).</p>
  <p class="ltrs-br-ltr-br-body-text">We decided to start bright light therapy in the hope of improving his negative symptoms. Negative and depressive symptoms were assessed with the Scale for the Assessment of Negative Symptoms (SANS)<span class="htm-cite"><a href="#ref4">4</a></span> and the Hamilton Depression Rating Scale (HDRS), respectively.<span class="htm-cite"><a href="#ref5">5</a></span> Before the first bright light therapy session, his SANS score was 99 and HDRS score was 12. According to the report of Aichhorn et al,<span class="htm-cite"><a href="#ref2">2</a></span> bright light therapy with 10,000 lux was administered in the hospital for 1 hour from 7:30 <span class="smallcaps">am</span> to 8:30 <span class="smallcaps">am</span>, 5 days per week, for 4 weeks. After starting bright light therapy, he began to respond more quickly to our questions, and impoverishment of thought mildly improved. While he still spent most of his time sitting in his room, he also began to watch television programs in the living room. His medication was not changed throughout the 4-week bright light therapy period. Following the 4-week treatment period, his SANS score decreased to 88 and HDRS score to 8. The SANS consists of 5 subscales (alogia, affective flattening, avolition, anhedonia/asociality, and attention impairment), and all subscale scores decreased with bright light therapy (<span class="callout"><a href="#" onclick="createFigure('f1'); return false;">Figure 1</a></span>). Bright light therapy was safe in our patient and did not cause psychotic exacerbation. Follow-up assessment was performed 16 weeks after the completion of bright light therapy. His SANS score did not change, and negative symptoms were not exacerbated during follow-up periods.</p>
  <div id="figure" class="right"> <a href="#" onclick="createFigure('f1'); return false;"><img src="17l02117F1.gif" alt="Figure 1" id="f1" border="0" /></a>
    <p class="click-to-enlarge">Click figure to enlarge</p>
  </div>
  <p class="ltrs-br-ltr-br-body-text">&nbsp;</p>
  <p class="ltrs-br-ltr-br-body-text">Bright light therapy is known to improve depressive symptoms of several disorders such as seasonal affective disorder, nonseasonal depression, and bipolar depression.<span class="htm-cite"><a href="#ref6">6</a></span> Negative symptoms such as alogia and avolition have been reported to correlate with depression.<span class="htm-cite"><a href="#ref7">7</a></span> In our patient, SANS subscale scores, which correlated with depression (alogia, avolition), decreased with bright light therapy. Interestingly, negative symptoms that do not overlap with depression (affective flattening, anhedonia/asociality, and attention impairment) were also improved by bright light therapy (see <span class="callout"><a href="#" onclick="createFigure('f1'); return false;">Figure 1</a></span>). It is probable that while the improvement of negative symptoms can be attributed to improvement in depressive symptoms, bright light therapy directly improved negative symptoms as well. The effect of bright light therapy for negative symptoms is still controversial.<span class="htm-cite"><a href="#ref2">2</a>,<a href="#ref3">3</a></span> Further studies are needed to clarify the effect of bright light therapy for negative symptoms.</p>
  <p class="ltrs-br-ltr-br-body-text">In conclusion, this case suggests that bright light therapy improves negative symptoms in some patients with residual schizophrenia.</p>
  <p class="references_references-heading"><span class="smallcaps">References</span></p>
  <p class="references-references-text-1-9"><a name="ref1"></a><span class="htm-ref"> 1.&#9;</span>Kraepelin E. <span class="italic">Lecture III, Dementia Praecox: Lectures on Clinical Psychiatry</span>. New York, NY: Wiliam Wood; 1917:21–29.</p>
  <p class="references-references-text-1-9"><a name="ref2"></a><span class="htm-ref"> 2.&#9;</span>Aichhorn W, Stelzig-Schoeler R, Geretsegger C, et al. Bright light therapy for negative symptoms in schizophrenia: a pilot study. <span class="italic">J&#160;Clin Psychiatry</span>. 2007;68(7):1146. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17685757&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="http://dx.doi.org/10.4088/JCP.v68n0726a"><span class="pubmed-crossref">doi:10.4088/JCP.v68n0726a</span></a></p>
  <p class="references-references-text-1-9"><a name="ref3"></a><span class="htm-ref"> 3.&#9;</span>Roopram SM, Burger AM, van Dijk DA, et al. A pilot study of bright light therapy in schizophrenia. <span class="italic">Psychiatry Res</span>. 2016;245:317–320. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27568303&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="http://dx.doi.org/10.1016/j.psychres.2016.07.034"><span class="pubmed-crossref">doi:10.1016/j.psychres.2016.07.034</span></a></p>
  <p class="references-references-text-1-9"><a name="ref4"></a><span class="htm-ref"> 4.&#9;</span>Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. <span class="italic">Br J Psychiatry suppl</span>. 1989;155(7):49–58. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2695141&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a></p>
  <p class="references-references-text-1-9"><a name="ref5"></a><span class="htm-ref"> 5.&#9;</span>Hamilton M. A rating scale for depression. <span class="italic">J&#160;Neurol Neurosurg Psychiatry</span>. 1960;23:56–62. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14399272&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a> <a href="http://dx.doi.org/10.1136/jnnp.23.1.56"><span class="pubmed-crossref">doi:10.1136/jnnp.23.1.56</span></a></p>
  <p class="references-references-text-1-9"><a name="ref6"></a><span class="htm-ref"> 6.&#9;</span>Prasko J. Bright light therapy. <span class="italic">Neuroendocrinol Lett</span>. 2008;29(suppl 1):33–64. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19029878&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a></p>
  <p class="references-references-text-1-9"><a name="ref7"></a><span class="htm-ref"> 7.&#9;</span>Brébion G, Amador X, Smith M, et al. Depression, psychomotor retardation, negative symptoms, and memory in schizophrenia. <span class="italic">Neuropsychiatry Neuropsychol Behav Neurol</span>. 2000;13(3):177–183. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10910088&amp;dopt=Abstract"><span class="pubmed-crossref">PubMed</span></a></p>
  <p class="ltrs-br-ltr-br-author"><span class="bold">Hirofumi Hirakawa, MD</span><span class="superscript">a,b</span></p>
  <p class="ltrs-br-ltr-br-author"><a href="mailto:hira-hiro@oita-u.ac.jp">hira-hiro@oita-u.ac.jp</a></p>
  <p class="ltrs-br-ltr-br-author"><span class="bold">Takeshi Terao, MD, PhD</span><span class="superscript">a</span></p>
  <p class="ltrs-br-ltr-br-author"><span class="bold">Shozo Fujii, MD, PhD</span><span class="superscript">b</span></p>
  <p class="ltrs-br-ltr-br-author"><span class="bold">Hirotaka Mukasa, MD, PhD</span><span class="superscript">b</span></p>
  <p class="end-matter"><span class="superscript">a</span>Department of Neuropsychiatry, Oita University Faculty of Medicine, Yufu, Oita, Japan</p>
  <p class="end-matter"><span class="superscript">b</span>Oosada Hospital, Nakatsu, Oita, Japan</p>
  <p class="end-matter"><span class="bold-italic">Potential conflicts of interest: </span>None.</p>
  <p class="end-matter"><span class="bold-italic">Funding/support:</span> None.</p>
  <p class="end-matter"><span class="bold-italic">Patient consent: </span>Permission was received from the patient to present the case, and the information was de-identified to protect anonymity.</p>
  <p class="end-matter"><span class="bold-italic">Published online:</span> September 7, 2017.</p>
  <p class="end-matter"><span class="italic">Prim Care Companion CNS Disord 2017;19(5):17l02117</span></p>
  <p class="doi-line"><span class="italic">https://doi.org/</span><span class="doi">10.4088/PCC.17l02117</span></p>
  <p class="end-matter"><span class="italic">© Copyright 2017 Physicians Postgraduate Press, Inc.</span></p>
</div>
Manage Subscriptions
/_layouts/images/ReportServer/Manage_Subscription.gif
/PCC/article/_layouts/ReportServer/ManageSubscriptions.aspx?list={ListId}&ID={ItemId}
0x80
0x0
FileType
rdl
350
Manage Data Sources
/PCC/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rdl
351
Manage Shared Datasets
/PCC/article/_layouts/ReportServer/DatasetList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rdl
352
Manage Parameters
/PCC/article/_layouts/ReportServer/ParameterList.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
353
Manage Processing Options
/PCC/article/_layouts/ReportServer/ReportExecution.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
354
Manage Cache Refresh Plans
/PCC/article/_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
355
View Report History
/PCC/article/_layouts/ReportServer/ReportHistory.aspx?list={ListId}&ID={ItemId}
0x0
0x40
FileType
rdl
356
View Dependent Items
/PCC/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsds
350
Edit Data Source Definition
/PCC/article/_layouts/ReportServer/SharedDataSource.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsds
351
View Dependent Items
/PCC/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
350
Manage Clickthrough Reports
/PCC/article/_layouts/ReportServer/ModelClickThrough.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
352
Manage Model Item Security
/PCC/article/_layouts/ReportServer/ModelItemSecurity.aspx?list={ListId}&ID={ItemId}
0x0
0x2000000
FileType
smdl
353
Regenerate Model
/PCC/article/_layouts/ReportServer/GenerateModel.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
smdl
354
Manage Data Sources
/PCC/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
smdl
351
Load in Report Builder
/PCC/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderModelContext&list={ListId}&ID={ItemId}
0x0
0x2
FileType
smdl
250
Edit in Report Builder
/_layouts/images/ReportServer/EditReport.gif
/PCC/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderReportContext&list={ListId}&ID={ItemId}
0x0
0x4
FileType
rdl
250
Edit in Report Builder
/PCC/article/_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderDatasetContext&list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
250
Manage Caching Options
/PCC/article/_layouts/ReportServer/DatasetCachingOptions.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
350
Manage Cache Refresh Plans
/PCC/article/_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}&IsDataset=true
0x0
0x4
FileType
rsd
351
Manage Data Sources
/PCC/article/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}
0x0
0x20
FileType
rsd
352
View Dependent Items
/PCC/article/_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}
0x0
0x4
FileType
rsd
353
Compliance Details
javascript:commonShowModalDialog('{SiteUrl}/_layouts/itemexpiration.aspx?ID={ItemId}&List={ListId}', 'center:1;dialogHeight:500px;dialogWidth:500px;resizable:yes;status:no;location:no;menubar:no;help:no', function GotoPageAfterClose(pageid){if(pageid == 'hold') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/hold.aspx?ID={ItemId}&List={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/Reporting.aspx?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/expirationconfig.aspx?ID={ItemId}&List={ListId}'); return false;}}, null); return false;
0x0
0x1
ContentType
0x01
898
Document Set Version History
javascript:SP.UI.ModalDialog.ShowPopupDialog('{SiteUrl}/_layouts/DocSetVersions.aspx?List={ListId}&ID={ItemId}')
0x0
0x0
ContentType
0x0120D520
330
Send To other location
javascript:GoToPage('{SiteUrl}/_layouts/docsetsend.aspx?List={ListId}&ID={ItemId}')
0x0
0x0
ContentType
0x0120D520
350

Information Links

Terms of Use | Privacy Policy | Information for Authors (JCP) | Information for Authors (PCC) | Reprints and Permissions | CNS Job Market | Information for Advertisers | Media Relations | PPP COVID-19 Statement

Help

Contact us | Unsubscribe from Elerts | Customer Service | FAQ | About JCP | About PCC | About Psychiatrist.com

Our Family of Sites

Psychiatrist.com | The Journal of Clinical Psychiatry | The Primary Care Companion | The CME Institute | Strong Veterans
Anonymous